Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Psilocybin - Core One Labs

Next Previous
Drug Profile

Psilocybin - Core One Labs

Latest Information Update: 28 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Core One Labs
  • Developer Core One Labs; Lobe Sciences; University of Miami
  • Class Analgesics; Anti-infectives; Anti-inflammatories; Antidepressants; Antineoplastics; Antipsychotics; Anxiolytics; Behavioural disorder therapies; Dimethylamines; Drug withdrawal therapies; Indoles; Mood stabilisers; Neuropsychotherapeutics; Organophosphorus compounds; Phytotherapies; Small molecules
  • Mechanism of Action ATP-binding cassette transporter modulators; Serotonin 5-HT2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Post-traumatic stress disorders; Traumatic brain injuries
  • No development reported Mental disorders

Most Recent Events

  • 28 May 2025 No recent reports of development identified for research development in Mental-disorders in Canada (PO, Film)
  • 21 Jan 2022 Core One Labs files a patent application with the US PTO titled “Production of Psychedelic Compounds” for protection of its novel psilocybin production system
  • 28 Sep 2021 Preclinical trials in Post-traumatic stress disorders in USA (unspecified route) as of September 2021

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top